XML 81 R58.htm IDEA: XBRL DOCUMENT v3.25.2
Commitments and Contingencies (Additional Information) (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2013
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Apr. 30, 2023
Commitments and Contingencies [Line Items]            
Royalty expenses   $ 100,000 $ 0 $ 300,000 $ 26,000  
Finance lease liabilities     $ 0    
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]   Derivative Liability, Noncurrent   Derivative Liability, Noncurrent    
Lease Expense   $ 300,000 300,000 $ 1,000,000 1,100,000  
Additional ROU assets   2,049,000   2,225,000 2,943,000 $ 2,500,000
Corresponding lease liabilities   1,327,000   1,523,000 2,237,000 $ 2,500,000
GLOPERBA [Member]            
Commitments and Contingencies [Line Items]            
Due From Related Party       500,000    
Former Employee [Member]            
Commitments and Contingencies [Line Items]            
Agreement settlement payment       3,500,000    
Former Employee One[Member]            
Commitments and Contingencies [Line Items]            
Agreement settlement payment       $ 2,500,000    
Epoladerm [Member]            
Commitments and Contingencies [Line Items]            
Percentage on net sale       6.00%    
Probudur [Member]            
Commitments and Contingencies [Line Items]            
Percentage on net sale       6.00%    
Envelta [Member]            
Commitments and Contingencies [Line Items]            
Percentage on net sale       6.00%    
Product Development Agreement [Member] | Developers [Member]            
Commitments and Contingencies [Line Items]            
Royalty expenses   700,000 2,300,000 $ 9,900,000 8,500,000  
Accrued royalty payables   $ 3,800,000   4,000,000 2,400,000  
Agreement maturity date Oct. 02, 2028          
Agreement maturity renewal description The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon six months’ written notice. The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon six-months’ written notice.        
Product Development Agreement [Member] | Developers [Member] | Minimum [Member]            
Commitments and Contingencies [Line Items]            
Royalty payment percentage related to future years 25.00%          
Product Development Agreement [Member] | Developers [Member] | Maximum [Member]            
Commitments and Contingencies [Line Items]            
Royalty payment percentage related to future years 35.00%          
Product Development Agreement [Member] | Scilex Pharma [Member]            
Commitments and Contingencies [Line Items]            
Royalty expenses   $ 900,000 $ 2,400,000 $ 8,300,000 $ 8,300,000  
Non-cancelable Lease Agreements [Member] | Minimum [Member] | Research and Development Facilities [Member]            
Commitments and Contingencies [Line Items]            
Operating lease, remaining lease term   2 years 6 months   2 years 9 months 18 days    
Operating lease, lease term   3 years   3 years    
Non-cancelable Lease Agreements [Member] | Maximum [Member] | Research and Development Facilities [Member]            
Commitments and Contingencies [Line Items]            
Operating lease, lease term   5 years   5 years